logo/base Created with Sketch.
logo echosens
en
chevron Contact
English version chevron
Change region

FibroScan®-based Score: Fast™

Identification of at-risk NASH patients

chevron chevron
wave

Fast™ Target

Current NASH drug developments focus on patients with NASH at-risk of progression to cirrhosis or with compensated cirrhosis defined by Active Fibrotic NASH (NASH + NAS≥4 + F≥2).

Fast™ Construction

Fast™ combines FibroScan® examination results (LSM by VCTE™ & CAP™) with an easily accessible blood biomarker (AST) to help identify patients with active fibrotic-NASH, at the point-of-care, reducing invasive and costly procedures.

Fast™ Performance

Good to excellent performance in derivation cohort as well as in external validation cohorts from different clinical settings (NAFLD tertiary care unit, screening, bariatric surgery) and geographical origins (USA, Europe, Asia). Several publications advocate the use of Fast™.

chevron Read The Lancet publication on Fast™

Fast™: tried and trusted

quote

Improvements in Fast™ are consistent with amelioration of key histologic features of NASH, including both inflammation and fibrosis.

Publication Boursier et al. | Oral ILC (EASL) 2020 : Abstract AS075

quote

Fast™ score demonstrated good discrimination for fibrotic NASH in our cohort.

Publication Anand et al. | European Journal of Gastroenterology & Hepatology, 2020.

quote

I believe that Fast™ is a key element for NASH clinical trials by enabling to decrease the screen failure rate and would further be of high interest to identify patients eligible to treatments.

Yusuf Yilmaz | Professor and M.D. Gastroenterology and Hepatology, Turkey

chevron Discover the clinical evidence
chevron chevron

Webinar: Fast™ presented at ILC 2021

chevron Watch the replay

Fast™ is an in vitro diagnostic medical device according to directive 98/79/EC.Fast™ calculator is a tool for clinicians, computed from LSM and CAP (obtained from FibroScan® device) and AST blood parameter measurement, to aid in the identification of a patient with suspicion of NAFLD as being at risk for active fibrotic NASH (NASH+NAS≥4+F≥2). It was developed based on a prospective multicenter cohort and published in peer-reviewed literature. Fast™ is presented as an educational service intended for licensed healthcare professionals. While this score is about specific medical and health issues, it is not a substitute for or a replacement of personalized medical advice and is not intended to be used as the sole basis for making individualized medical or health-related decisions.

 

 

To access the Fast™ User Guides, connect to myfibroscan.com:
Scores > Fast™ > Learn more

chevron User Guides Fast™

Our liver health solutions

chevron Contact us